Methods for achieving an isolated electrical interface between an anterior surface of a microneedle structure and a posterior surface of a support structure

Information

  • Patent Grant
  • 12109032
  • Patent Number
    12,109,032
  • Date Filed
    Tuesday, March 6, 2018
    6 years ago
  • Date Issued
    Tuesday, October 8, 2024
    2 months ago
Abstract
A method for circumscribing an insulating barrier region around a singular conductive microneedle structure or plurality of conductive microneedle structures adhered to a fixed substrate for the purpose of spatially defining a conduit for the routing of an electrical signal from the surface of said microneedle or microneedles to the posterior surface of the substrate is disclosed herein. A microneedle-based electrochemical biosensors structure comprises a substrate, a microneedle biosensor, a primary electrically conductive element, a secondary electrically conductive element and an electrically insulative annular barrier.
Description
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

Not Applicable


BACKGROUND OF THE INVENTION
Field of the Invention

The present invention generally relates to methods for manufacturing microneedle structures.


Description of the Related Art

Microneedle-based electrochemical biosensor devices have witnessed increased development activity in recent years and rely on the interaction between an electrical signal and a biological analyte. However, to serve useful purposes, these devices must be fabricated using design topologies that are compatible with existing packaging methods. In this vein, current chip-scale implementations of microneedle biosensors (and drug delivery actuators, for that matter) require wire-bonding or flip-chip methods of establishing electrical contact with the active sensing (or transducing) element located on or within the microneedle structure. In spite of this approach, wire bonding and flip-chip methods are not compatible with useful embodiments of sensing/therapeutic capabilities as these modalities would serve to obstruct the microneedle surface and prevent reliable penetration of the stratum corneum. The current methodology allows for an alternative to wire-bonding and flip-chip methods of electrical interface by means of circumscribing electrically-conductive microneedles with an insulating barrier to facilitate a spatially-defined region that can be probed on the posterior surface of the substrate on which the microneedle elements are located.


Microneedle-based electrochemical biosensors represent a promising avenue towards the minimally-invasive quantification of a number of relevant analytes in the physiological fluid, such as interstitial fluid, blood, serum, and plasma. In such devices, an electrical signal is applied to the surface of a microneedle, which concomitantly instigates an electrochemical reaction to either oxidize or reduce an analyte or product of the analyte and a surface-immobilized intermediary. The resultant magnitude of potential or current arising from the redox reaction, which reflects the concentration of analyte in the physiological medium, is then routed to an external integrated circuit, module, or self-contained device for interpretation. In order to facilitate electrical interface between the skin-penetrating regions of the microneedle and a suitable location where the redox signal can be probed, conductive traces are spatially defined from the sensing region located on the microneedle surface to a pad located on the extremities of the substrate upon which the microneedles are secured. However, current chip-scale packaging techniques such as wire-bonding mandate that electrical leads be soldered on the same surface in which the microneedles are located; this can interfere with the insertion of the said microneedles due to increased standoff. On the other hand, flip-chip techniques mandate that the substrate be ‘flipped’ to facilitate electrical interface, which thereby serves to orient the microneedle structure(s) away from the intended application site and into the interior of the package itself. In order to maintain compatibility with existent packaging methods, the fabrication of said microneedle devices mandates that a spatially-defined conductive region be realized between the sensing surface located on the microneedle structure and the posterior surface of the substrate that the said microneedle is located. In accordance with current practice, this has proven difficult to remedy as the spatial definition of a suitable conduit providing electrical communication between two opposing sides of the substrate required modifications to the fabrication methodology.


Prior art solutions have been concerned with patterned, planar conductive traces routing the electrical signal from the microneedle surface to a spatially defined region (pad) suitable for probing/wire-bonding to facilitate implementation in an integrated circuit-style package. The said pad is located on the same surface as the microneedle structure, which, when attached to an external circuit with bonding wire, will cause increased standoff and prevent the microneedle structure from fully inserting into the viable epidermis or dermis. The trace is not routed through the substrate supporting said microneedle(s) and occupies the same surface as the microneedle.


U.S. Pat. No. 6,551,849 for a Method For Fabricating Arrays Of Micro-Needles discloses an array of micro-needles is created by forming an array pattern on the upper surface of a silicon wafer and etching through openings in the pattern to define micro-needle sized cavities having a desired depth. The mold thus formed may be filled with electrically conductive material, after which a desired fraction of the silicon wafer bulk is removed from the bottom-up by etching, to expose an array of projecting micro-needles. The mold may instead be filled with a flexible material to form a substrate useful in gene cell probing. An array of hollow micro-needles may be formed by coating the lower wafer surface with SiN, and etching through pattern openings in the upper surface down to the SiN layer, and then conformally coating the upper surface with thermal silicon dioxide. The SiN layer is then stripped away and a desired fraction of the bulk of the wafer removed from the bottom-up to expose an array of projecting hollow micro-needles.


U.S. Patent Publication Number 20140303471 for Non-Invasive Segmentable Three-Dimensional Microelectrode Array Patch For Neurophysiological Diagnostics And Therapeutic Stimulation discloses implementations disclosed herein provide for a microneedle electrode system comprising a microneedle electrode patch connected to external electronics. The microneedle electrode patch comprises a first flexible substrate having a plurality of conductive pads disposed thereon, a plurality of three-dimensional, individually addressable microneedle electrode arrays where each array has a plurality of microneedles extending from an upper surface thereof and a lower surface adapted to contact a corresponding one of the plurality of conductive pads disposed on the first substrate, and a second flexible substrate having a plurality of openings defined therein dimensioned to accommodate at least a portion of the upper surface of the microneedle electrode array from which the microneedles extend. Each of the conductive pads is disposed in electrical communication with a corresponding one of the plurality of microneedle electrode arrays and the first and second substrate are bonded together such that each one of the plurality of microneedle electrode arrays extends through a corresponding one of the plurality of openings defined in the second substrate.


U.S. Pat. No. 8,308,960 for Methods for Making Microneedles and Applications Thereof discloses a method of making vertically protruding elements on a substrate, said elements having a tip comprising at least one inclined surface and an elongated body portion extending between said substrate and said tip. The method comprises an anisotropic, crystal plane dependent etch forming said inclined surface(s); and an anisotropic, non crystal plane dependent etch forming said elongated body portion; combined with suitable patterning processes defining said protruding elements to have a predetermined base geometry.


U.S. Pat. No. 8,637,351 for Methods for Making Microneedles and Applications Thereof discloses a method of making vertically protruding elements on a substrate, said elements having a tip comprising at least one inclined surface and an elongated body portion extending between said substrate and said tip. The method comprises an anisotropic, crystal plane dependent etch forming said inclined surface(s); and an anisotropic, non crystal plane dependent etch forming said elongated body portion; combined with suitable patterning processes defining said protruding elements to have a predetermined base geometry.


BRIEF SUMMARY OF THE INVENTION

The current solution teaches of a means to implement a spatially-defined, conductive conduit between the sensing surface of a microneedle (or array of microneedles) located on a planar substrate and the opposing surface of said substrate. In doing so, the need to make ohmic contact with the microneedle-containing surface of the substrate is mitigated, which enables unobstructed insertion of the said microneedle (or array of microneedles) into the viable epidermis or dermis.


The technology described herein involves a method for circumscribing an insulating barrier region around a singular conductive microneedle structure or plurality of conductive microneedle structures adhered to a fixed substrate for the purpose of spatially defining a conduit for the routing of an electrical signal from the surface of said microneedle or microneedles to the posterior surface of said substrate.


One aspect of the present invention is a microneedle-based electrochemical biosensors structure. The structure comprises a substrate, a microneedle biosensor, a primary electrically conductive element, a secondary electrically conductive element and an electrically insulative annular barrier. The substrate is composed of an electrically conducting material, the substrate comprising an anterior surface and a posterior surface. The microneedle biosensor has a length ranging from 20 microns to 2000 microns. The microneedle biosensor comprises a penetrating end and a posterior end. The microneedle biosensor protrudes from the anterior surface of the substrate and having a portion within the substrate. The primary electrically conductive element is located on the penetrating end of the microneedle biosensor. The secondary electrically conductive element is located on the posterior end of the microneedle biosensor. The electrically insulative annular barrier surrounds the portion of microneedle biosensor that is embedded in the substrate to electrically isolate the microneedle biosensor from the substrate.


Another aspect of the present invention is a microneedle-based electrochemical biosensors structure. The structure comprises a substrate, a plurality of microneedle biosensors, a primary electrically conductive element, a secondary electrically conductive element and an electrically insulative annular barrier. The substrate is composed of an electrically conducting material, the substrate comprising an anterior surface and a posterior surface. Each of the plurality of microneedle biosensors has a length ranging from 20 microns to 2000 microns. Each microneedle biosensor comprises a penetrating end and a posterior end, each microneedle biosensor protruding from the anterior surface of the substrate and having a portion within the substrate. The primary electrically conductive element is located on the penetrating end of each microneedle biosensor. The secondary electrically conductive element is located on the posterior end of each microneedle biosensor. The electrically insulative annular barrier surrounds the portion of each microneedle biosensor that is embedded in the substrate to electrically isolate the microneedle biosensor from the substrate.


Yet another aspect of the present invention is a microneedle-based electrochemical biosensors structure with a printed circuit board (PCB). The structure comprises a PCB, a substrate, a plurality of microneedle biosensors, a primary electrically conductive element, a secondary electrically conductive element, an electrically insulative annular barrier and a plurality of phase-change conductive interconnects. The PCB comprises a pad, at least one via and a plurality of traces. The substrate is composed of an electrically conducting material, the substrate comprising an anterior surface and a posterior surface. Each of the plurality of microneedle biosensors has a length ranging from 20 microns to 2000 microns. Each microneedle biosensor comprises a penetrating end and a posterior end, each microneedle biosensor protruding from the anterior surface of the substrate and having a portion within the substrate. The primary electrically conductive element is located on the penetrating end of each microneedle biosensor. The secondary electrically conductive element is located on the posterior end of each microneedle biosensor. The electrically insulative annular barrier surrounds the portion of each microneedle biosensor that is embedded in the substrate to electrically isolate the microneedle biosensor from the substrate. The phase-change conductive interconnect is positioned between the pad of the printed circuit board and the secondary electrically conductive element.


Yet another aspect of the present invention is a microneedle-based electrochemical biosensors structure with a printed circuit board (PCB). The structure comprises a PCB, a substrate, a microneedle biosensor, a primary electrically conductive element, a secondary electrically conductive element, an electrically insulative annular barrier and a plurality of phase-change conductive interconnects. The PCB comprises a pad, at least one via and a plurality of traces. The substrate is composed of an electrically conducting material, the substrate comprising an anterior surface and a posterior surface. Each of the plurality of microneedle biosensors has a length ranging from 20 microns to 2000 microns. Each microneedle biosensor comprises a penetrating end and a posterior end, each microneedle biosensor protruding from the anterior surface of the substrate and having a portion within the substrate. The primary electrically conductive element is located on the penetrating end of each microneedle biosensor. The secondary electrically conductive element is located on the posterior end of each microneedle biosensor. The electrically insulative annular barrier surrounds a portion of the length of each microneedle biosensor to electrically isolate the microneedle biosensor from the substrate. Each of the phase-change conductive interconnects is positioned between the pad of the printed circuit board and the secondary electrically conductive element of each microneedle biosensor.


Yet another aspect of the invention is the jetting of solder balls, spheres, or solder bumps onto the secondary conductive element on located on the posterior end of each microneedle biosensor to facilitate solder reflow with pads located on the IC, IC package, chip carrier, or PCB. Said solder balls, spheres, or solder bumps may be simultaneously jetted onto the secondary conductive element and heated by means of a reflow laser to facilitate adhesion of said solder balls, spheres, or solder bumps onto the underlying secondary conductive element. Optionally, said process can be implemented on a wafer scale or by means of wafer-level solder balling to accelerate the rate at which said jetting occurs. In such a process, solder balls, spheres, or solder bumps are attached, simultaneously, to all the secondary conductive elements located on the posterior ends of each microneedle biosensor on a wafer substrate in a highly parallelized fashion.


Yet another aspect of the invention is the attachment of an electrically-conductive epoxy to at least one of a secondary conductive element on located on the posterior end of each microneedle biosensor and a pad located on an IC, IC package, chip carrier, or PCB. Optionally, heat can be employed to reflow the electrically-conductive epoxy. Optionally, the electrically-conductive epoxy can cure following UV exposure. Optionally, the electrically-conductive epoxy can cure following remaining at ambient conditions for a defined period of time.


Yet another aspect of the invention is the incorporation of a conducting metallic pillar into the solder ball, sphere, or bump to increase the standoff between the secondary electrically conductive element located on the posterior end of each microneedle biosensor and the underlying pad located on the surface of an IC, IC package, chip carrier, or PCB.


Yet another aspect of the invention is the selection of the secondary conductive element on located on the posterior end of each microneedle biosensor to facilitate stud bumping or the attachment of solder balls. Said conductive element can be selected from, for example, gold, nickel, aluminum, and palladium or be comprised of a bi- or tri-metallic alloy of any permutation of the same.


Yet another aspect of the invention is the selection of the pad material located on the IC, IC package, chip carrier, or PCB. The selection of the material is to facilitate stud bumping or the attachment of solder balls. Said pad material can be selected from, for example, gold, nickel, aluminum, and palladium or be comprised of a bi- or tri-metallic alloy of any permutation of the same.


Having briefly described the present invention, the above and further objects, features and advantages thereof will be recognized by those skilled in the pertinent art from the following detailed description of the invention when taken in conjunction with the accompanying drawings.





BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS


FIG. 1 is a cross-sectional view of a singular electrically-conductive microneedle structure located on the anterior surface of an electrically-conductive substrate.



FIG. 1A is a cross-sectional view of multiple microneedle structures located on the anterior surface of an electrically-conductive substrate.



FIG. 2 is a top plan view of an anterior surface of a substrate featuring a microneedle element circumscribed by an insulating barrier.



FIG. 2A is a top plan view of an anterior surface of a substrate featuring microneedle elements circumscribed by an insulating barrier.



FIG. 3 is a view of a posterior surface of a substrate featuring a secondary electrically-conductive element (pad) circumscribed by an insulating barrier.



FIG. 4 is a preliminary phase of a fabrication process implemented to define insulating barrier regions to electrically isolate a microneedle and underlying substrate to facilitate electrical probing from the posterior surface of the substrate.



FIG. 4A is a first step of the fabrication process in which a substrate is etched from a single side.



FIG. 4B is a second step of the fabrication process in which the etched void is filled with an insulating material.



FIG. 4C is a third step of the fabrication process in which an opposing side of the substrate is etched.



FIG. 4D is a fourth step of the fabrication process in which the opposing side void is filled with an insulating material.



FIG. 5 is a cross-sectional view of singular electrically-conductive microneedle structures, electrically-isolated from one another, and located on the anterior surface of an electrically-conductive substrate.



FIG. 6 is a cross-sectional view of a prior art flip-chip bonding configuration and method of interface.



FIG. 6A is a top plan view of a prior art packaged microneedle sensing device.



FIG. 7 is a cross-sectional view of the prior art wire bonding configuration and method of interface.



FIG. 7A is a top plan view of a prior art packaged microneedle sensing device.



FIG. 8 is a cross-sectional view of two electrically-isolated microneedles occupying the same substrate to illustrate a solder ball/stud bumping configuration and method of interface.





DETAILED DESCRIPTION OF THE INVENTION

The technology disclosed herein addresses the above challenge via the implementation of fully-insulating barriers that circumscribe and thereby electrically isolate the microneedle (or plurality of microneedles) from other locations on the substrate. In this manner, an electrical signal can be routed from a spatially-defined electrically-conductive region located on the tip of the microneedle (or plurality of microneedles) to the posterior surface of the substrate to facilitate probing and device-level packaging while leaving the surface containing the microneedle(s) exposed to enable skin penetration and subsequent sensing operation. An electrically-conductive substrate (i.e. semiconductor wafer, polymer wafer, glass wafer, ceramic wafer, or metal wafer) containing microneedles on the anterior surface (each microneedle featuring a primary electrically-conductive element (i.e. metal, semiconductor, conducting polymer) in ohmic contact with the conductive substrate) and a secondary electrically-conductive element (i.e. metal, semiconductor, conducting polymer) on the posterior surface undergoes an etching process whereby substrate material in an annular region circumscribing one or more conductive microneedles is removed. The trench created in this process, which must be less than the thickness of the substrate, is filled with an insulating material (growth of a native oxide or deposition of an electrically-insulating compound). The substrate is then flipped to expose the opposing surface and another trench (having identical geometric features to the aforementioned trench) is etched to a depth sufficient to access the opposing filled trench. This trench is subsequently filled with an insulating material (growth of a native oxide or deposition of an electrically-insulating compound). In this fashion, an isolated, electrically-conducting region extending from the primary electrical contact (located on or within the microneedle structure) to the secondary electrical contact is realized. The secondary electrically-conductive element is either probed directly, bonded to solder bumps and exposed to solder reflow to attach to pads populating a printed circuit board (PCB), or bonded to solder bumps located within an integrated circuit package. The IC package can be probed directly, placed in a socket, or soldered onto a printed circuit board to facilitate electrochemical analysis (control of the redox reaction and readout of the signal). This approach is in direct analogy to conductive through-silicon vias implemented in silicon-based semiconductor substrates, which are widely used in 3-dimensional semiconductor manufacturing and wafer-level packaging. The differentiating feature in the current innovation resides in the approach of ‘filling’ the via with insulating material and circumscribing an enclosed region with said via to facilitate full electrical isolation from other portions of the substrate not located within the enclosed region.


The structure preferably includes a substrate, a microneedle biosensor, a primary electrically-conductive element, a secondary electrically-conductive element, and an electrically-insulative annular barrier. The substrate is fabricated from an intrinsically conducting or semiconducting material (i.e. doped semiconductor wafer, conducting polymer wafer, glass wafer, ceramic wafer, or metal wafer). The substrate features anterior and posterior surfaces. The microneedle biosensor is a defined protrusion from the anterior surface of the substrate possessing vertical extent of between 20 and 2000 μm and designed to penetrate the stratum corneum or other biological tissue to access a viable physiological fluid (such as blood, plasma, serum, or interstitial fluid). The primary electrically-conductive element is a defined conductive region located on the surface of said microneedle structure, intended to react, either directly or indirectly, with a chemical analyte in the physiological medium. The secondary electrically-conductive element is a defined conductive region located on the posterior surface of said substrate, intended to enable ohmic contact with a electrical probing mechanism or bonding/soldering to an integrated circuit package or printed circuit board. The electrically-insulative annular barrier is an annular barrier, defined via an etching, milling, machining, ablative, or otherwise subtractive processes, filled with an electrically insulating material to spatially define a region of conductivity within the annulus and provide isolation with the substrate located to the exterior of said annulus. The electrically insulating material can be filled by means of the oxidative growth of a native, non-conducting oxide, nitride, or other alloy or the additive deposition of the same.


The method for manufacturing the structure includes etching, milling, machining, or ablating of an anterior trench in which an etching process is used on the anterior surface of a conductive substrate to remove material in a defined patterned region, thereby defining an anterior trench. The method also includes implementation of an insulating material in anterior trench in which an insulating layer is grown or deposition of an insulating material in said anterior trench. The method also includes etching, milling, machining, or ablating of the posterior trench in which one of the etching, milling, machining, or ablating process is used on the posterior surface of said conductive substrate to remove material in a defined patterned region, thereby defining a posterior trench. Substrate material is etched, milled, machined, or ablated to a depth that is equal to or greater than the difference between the substrate thickness and the depth of the anterior trench, but less than the overall thickness of the substrate. The method also includes implementation of an insulating material in posterior trench in which an insulating layer is grown or deposition of an insulating material in said posterior trench.



FIGS. 1 and 1A illustrate a singular electrically-conductive microneedle structure 1 and a plurality of microneedle structures 1a and 1b located on the anterior surface 16 of an electrically-conductive substrate 15. Insulating barriers 20 are shown and possess a vertical extent equal to the thickness of the substrate 15. A primary electrically-conductive sensing element 5 is located on the microneedle structure 10 and a secondary electrically-conductive probing element (pad) 6 is located on the posterior surface 17 of the substrate 15. The substrate 15 is preferably selected from the group consisting of a semiconductor wafer, a rigid polymer, a flexible polymer, glass, ceramic, or metal. The electrically conductive element 5 and 6 preferably includes a metal, doped region of semiconductor, or conducting polymer. The microneedle 10 comprises a protrusion of vertical extent of between 20 and 2000 μm from the base 19 of the substrate 15 and designed to penetrate a biological interface.



FIGS. 2 and 2A illustrate top plan views of the anterior surface 16 of the substrate 15 featuring the microneedle element 10 or elements 10a and 10b circumscribed by an insulating barrier 20.



FIG. 3 is a view of the posterior surface 17 of the substrate 17 featuring the secondary electrically-conductive element (pad) 6 circumscribed by an insulating barrier 20.



FIGS. 4, 4A, 4B, 4C and 4D illustrate a preferred fabrication process implemented to define insulating barrier regions to electrically isolate the microneedle and underlying substrate to facilitate electrical probing from the posterior surface of the substrate. As shown in FIG. 4, a substrate 15 has a microneedle 10 extending upward. A primary electrically-conductive sensing element 5 is located on an anterior surface 16 of the microneedle structure 1 and a secondary electrically-conductive probing element (pad) 6 is located on the posterior surface 17 of the substrate 15. As shown in FIG. 4, voids 40 are etched from the substrate 15. As shown in FIG. 4B, insulating material 45 fills the voids 40. As shown in FIG. 4C, voids 40 are etched from a posterior surface 17 of the substrate 15. As shown in FIG. 4D, insulating material 45 fills the voids 40 in the posterior surface 17 of the substrate 15.



FIG. 5 is a cross-sectional view of a singular electrically-conductive microneedle structures 1a and 1b, electrically-isolated from one another, located on the anterior surface of an electrically-conductive substrate 15. Insulating barriers 20 are shown and possess a vertical extent equal to the sum of the thickness of the substrate 15 and the height of the microneedle 10. A primary electrically-conductive sensing element 5 is located on the distal extent of the microneedle 10 and a secondary electrically-conductive probing element (pad) 6 is located on the posterior surface 17 of the substrate 15, directly underneath the primary electrically-conductive sensing element 6.



FIGS. 6 and 6A illustrate the prior art flip-chip bonding configuration and method of interface of a packaged microneedle sensing device. A substrate 60 has a metal surface trace 69, a surface insulation 61, an opening for a microneedle 62, a package substrate/housing 65, a flip chip bond 63 and an external package connection pad/connect 64.



FIGS. 7 and 7A illustrate the prior art wire bonding configuration and method of interface of a packaged microneedle sensing device. A substrate 60 has a metal surface trace 75, a surface insulation 61, a package substrate/housing 65, a wire bond 70, an external package connection pad/connect 64, and an internal package contact 74.



FIG. 8 is an illustration of a solder ball/stud bumping configuration and method of interface. Two electrically-isolated microneedle structures 1a and 1b occupying the same substrate 15, one structure 1b of which is mounted and interfaced using a via 83 between two opposing pads 81a and 81b to gain electrical access to the primary electrically-conductive element 5 on the posterior surface of the printed circuit board/package/chip carrier 85, and the other structure 1a of which is mounted and interfaced using two offset pads 81c and 81d connected by a trace 82 to gain electrical access to the primary electrically-conductive element 5 on the anterior surface 16 of the printed circuit board/package/chip carrier 85.


One embodiment is a microneedle-based electrochemical biosensors structure 1 with a printed circuit board (PCB) 85. The structure 1 comprises a PCB 85, a substrate 15, a microneedle biosensor 10, a primary electrically conductive element 5, a secondary electrically conductive element 6, an electrically insulative annular barrier 20 and a plurality of phase-change conductive interconnects. The phase-change conductive interconnect is preferably one of a solder ball 80 and a conductive epoxy. The PCB 85 comprises a pad 81, at least one via 83 and a plurality of traces 82. The substrate 15 is preferably composed of an electrically conducting material. The substrate preferably comprises an anterior surface 16 and a posterior surface 17. Each of the plurality of microneedle biosensors 10 has a length ranging from 20 microns to 2000 microns. Each microneedle biosensor 10 comprises a penetrating end and a posterior end. Each microneedle biosensor 10 protrudes from the anterior surface 16 of the substrate 15 and has a portion within the substrate 15. The primary electrically conductive element 5 is located on the penetrating end of each microneedle biosensor 10. The secondary electrically conductive element 6 is located on the posterior end of each microneedle biosensor 10. The electrically insulative annular barrier 20 surrounds the length of each microneedle biosensor 10 to electrically isolate the microneedle biosensor 10 from the substrate 15. Each of the phase-change conductive interconnects 80 is positioned between the pad 81 of the PCB 85 and the secondary electrically conductive element 6 of each microneedle biosensor 10.


The secondary electrically conductive element 6 is preferably composed of a metal, a doped region of semiconductor, or a conducting polymer.


Each microneedle biosensor 10 is preferably configured to penetrate a stratum corneum of a mammal.


The biological interface is preferably a stratum corneum.


The substrate 15 is preferably composed of a semiconductor wafer, a rigid polymer, a flexible polymer, a glass material, a ceramic material, or a metal material.


McCanna et al., U.S. patent application Ser. No. 14/843,926, filed on Sep. 2, 2015, for a Miniaturized Sub-Nanoampere Sensitivity Low-Noise Potentiostat System is hereby incorporated by reference in its entirety.


Windmiller et al., U.S. patent application Ser. No. 14/955,850, filed on Dec. 1, 2015, for a Method And Apparatus For Determining Body Fluid Loss is hereby incorporated by reference in its entirety.


Windmiller, U.S. patent application Ser. No. 15/177,289, filed on Jun. 8, 2016, for a Methods And Apparatus For Interfacing A Microneedle-Based Electrochemical Biosensor With An External Wireless Readout Device is hereby incorporated by reference in its entirety.


Wang et al., U.S. Patent Publication Number 20140336487 for a Microneedle Arrays For Biosensing And Drug Delivery is hereby incorporated by reference in its entirety.


Windmiller, U.S. patent application Ser. No. 15/590,105 for a Tissue-Penetrating Electrochemical Sensor Featuring A Co Electrodeposited Thin Film Comprised Of A Polymer And Bio-Recognition Element is hereby incorporated by reference in its entirety.


PCT Application Number PCT/US17/55314 for an Electro-Deposited Conducting Polymers For The Realization Of Solid-State Reference Electrodes For Use In Intracutaneous And Subcutaneous Analyte-selective Sensors is hereby incorporated by reference in its entirety.


From the foregoing it is believed that those skilled in the pertinent art will recognize the meritorious advancement of this invention and will readily understand that while the present invention has been described in association with a preferred embodiment thereof, and other embodiments illustrated in the accompanying drawings, numerous changes modification and substitutions of equivalents may be made therein without departing from the spirit and scope of this invention which is intended to be unlimited by the foregoing except as may appear in the following appended claim. Therefore, the embodiments of the invention in which an exclusive property or privilege is claimed are defined in the following appended claims.

Claims
  • 1. A microneedle-based electrochemical biosensor structure, the structure comprising: a printed circuit board comprising a pad, at least one via and a plurality of traces;a substrate composed of an electrically conducting material;a microneedle having a first portion within the substrate and a second portion extending from an anterior surface of the substrate, the first portion comprising a posterior end of the microneedle, the second portion comprising a columnar body and a penetrating end of the microneedle, the penetrating end being at a distal end of the microneedle and separated from the anterior surface of the substrate by a length of the columnar body;a primary electrically conductive element located on the penetrating end of the microneedle;a secondary electrically conductive element located on the posterior end of the microneedle and on a posterior surface of the substrate;an electrically insulative annular barrier surrounding the first portion of the microneedle and the length of the columnar body of the second portion of the microneedle; anda phase-change conductive interconnect positioned between the pad of the printed circuit board and the secondary electrically conductive element,wherein the microneedle is electrically conductive and the electrically insulative annular barrier electrically isolates the microneedle from the substrate.
  • 2. The structure according to claim 1, wherein the substrate is composed of a semiconductor wafer, a rigid polymer, a flexible polymer, a glass material, a ceramic material, or a metal material.
  • 3. The structure according to claim 1, wherein the primary electrically conductive element is composed of a metal, a doped region of semiconductor, or a conducting polymer.
  • 4. The structure according to claim 1, wherein the secondary electrically conductive element is composed of a metal, a doped region of semiconductor, or a conducting polymer.
  • 5. The structure according to claim 1, wherein the microneedle is configured to penetrate a stratum corneum of a mammal.
  • 6. The structure according to claim 1, wherein the secondary electrically conductive element is circumscribed by the electrically insulative annular barrier.
  • 7. The structure according to claim 1, wherein the second portion of the microneedle has a total length ranging from 20 microns to 2000 microns.
  • 8. The structure according to claim 1, wherein the primary electrically conductive element is in contact with the microneedle and located only on the penetrating end of the microneedle.
  • 9. The structure according to claim 1, wherein the microneedle comprises only a single primary electrically conductive element.
  • 10. A microneedle-based electrochemical biosensor structure, the structure comprising: a printed circuit board comprising a pad, at least one via and a plurality of traces;a substrate composed of an electrically conducting material;a plurality of electrically conductive microneedles, each microneedle having a first portion within the substrate and a second portion extending from an anterior surface of the substrate, the first portion comprising a posterior end of the microneedle, the second portion comprising a columnar body and a penetrating end of the microneedle, the penetrating end being at a distal end of the microneedle and separated from the anterior surface of the substrate by a length of the columnar body;a plurality of primary electrically conductive elements, wherein each of the primary electrically conductive elements is located on a penetrating end of a respective microneedle of the plurality of microneedles;a plurality of secondary electrically conductive elements located on a posterior surface of the substrate, wherein each of the secondary electrically conductive elements is located on the posterior end of a respective microneedle of the plurality of microneedles;a plurality of electrically insulative annular barriers, wherein the first portion and the length of the columnar body of the second portion of each microneedle of the plurality of microneedles is surrounded by a respective electrically insulative annular barrier of the plurality of electrically insulative annular barriers; anda plurality of phase-change conductive interconnects, each of the phase-change conductive interconnects positioned between the pad of the printed circuit board and a respective secondary electrically conductive element of the plurality of secondary electrically conductive elements.
  • 11. The structure according to claim 10, wherein the substrate is composed of a semiconductor wafer, a rigid polymer, a flexible polymer, a glass material, a ceramic material, or a metal material.
  • 12. The structure according to claim 10, wherein each of the primary electrically conductive elements is composed of a metal, a doped region of semiconductor, or a conducting polymer.
  • 13. The structure according to claim 10, wherein each of the secondary electrically conductive elements is composed of a metal, a doped region of semiconductor, or a conducting polymer.
  • 14. The structure according to claim 10, wherein each microneedle is configured to penetrate a stratum corneum of a mammal.
  • 15. The structure according to claim 10, wherein each of the phase-change conductive interconnects of the plurality of phase-change conductive interconnects is one of a solder ball and a conductive epoxy.
  • 16. The structure according to claim 10, wherein each of the secondary electrically conductive elements of the plurality of secondary electrically conductive elements is circumscribed by a respective electrically insulative annular barrier of the plurality of electrically insulative annular barriers.
  • 17. The structure according to claim 10, wherein each microneedle of the plurality of microneedles is electrically-isolated from remaining microneedles of the plurality of microneedles.
  • 18. The structure according to claim 10, wherein the second portion of each microneedle of the plurality of microneedles has a total length ranging from 20 microns to 2000 microns.
  • 19. A microneedle-based electrochemical biosensor structure, the structure comprising: a substrate composed of an electrically conducting material;an electrically conductive microneedle having a first portion within the substrate and a second portion extending from an anterior surface of the substrate, the first portion comprising a posterior end of the microneedle, the second portion comprising a columnar body and a penetrating end of the microneedle, the penetrating end being at a distal end of the microneedle and separated from the anterior surface of the substrate by a length of the columnar body;a primary electrically conductive element located on the penetrating end of the microneedle;a secondary electrically conductive element located on the posterior end of the microneedle and on a posterior surface of the substrate; andan electrically insulative annular barrier surrounding the first portion of the microneedle and the length of the columnar body of the second portion of the microneedle, wherein the electrically insulative annular barrier electrically isolates the microneedle from the substrate.
  • 20. The structure according to claim 19, wherein the secondary electrically conductive element is circumscribed by the electrically insulative annular barrier.
CROSS REFERENCE TO RELATED APPLICATION

The present Application claims priority to U.S. Provisional Patent Application No. 62/470,204 filed on Mar. 11, 2017, which is hereby incorporated by reference in its entirety.

US Referenced Citations (438)
Number Name Date Kind
4305401 Reissmueller et al. Dec 1981 A
4323996 Ganter Apr 1982 A
4407295 Steuer et al. Oct 1983 A
4450842 Zick et al. May 1984 A
4908117 Kinlen et al. Mar 1990 A
4969468 Byers et al. Nov 1990 A
5035711 Aoki et al. Jul 1991 A
5131390 Sakaguchi et al. Jul 1992 A
5279543 Glikfeld et al. Jan 1994 A
5286364 Yacynych et al. Feb 1994 A
5540828 Yacynych Jul 1996 A
5730714 Guy et al. Mar 1998 A
5766132 Yasukawa et al. Jun 1998 A
5832410 Lin et al. Nov 1998 A
5869078 Baudino Feb 1999 A
5953306 Yi Sep 1999 A
6036055 Mogadam et al. Mar 2000 A
6091975 Daddona et al. Jul 2000 A
6132449 Lum et al. Oct 2000 A
6132499 Wong et al. Oct 2000 A
6132755 Eicher et al. Oct 2000 A
6139718 Kurnik et al. Oct 2000 A
6269053 Kawata et al. Jul 2001 B1
6284126 Kurnik et al. Sep 2001 B1
6364890 Lum et al. Apr 2002 B1
6413396 Yang et al. Jul 2002 B1
6465091 Ou-yang Oct 2002 B1
6471903 Sherman et al. Oct 2002 B2
6527762 Santini, Jr. et al. Mar 2003 B1
6551849 Kenney Apr 2003 B1
6587705 Kim et al. Jul 2003 B1
6599408 Chan et al. Jul 2003 B1
6603987 Whitson Aug 2003 B2
6611707 Prausnitz et al. Aug 2003 B1
6793789 Choi et al. Sep 2004 B2
6801041 Karinka et al. Oct 2004 B2
6814845 Wilson et al. Nov 2004 B2
6862466 Ackerman Mar 2005 B2
6908453 Fleming et al. Jun 2005 B2
7081195 Simpson et al. Jul 2006 B2
7097776 Raju Aug 2006 B2
7132054 Kravitz et al. Nov 2006 B1
7183068 Burson et al. Feb 2007 B2
7262068 Roy et al. Aug 2007 B2
7343188 Sohrab Mar 2008 B2
7344499 Prausnitz et al. Mar 2008 B1
7366556 Brister et al. Apr 2008 B2
7415299 Zimmermann et al. Aug 2008 B2
7429333 Chiou et al. Sep 2008 B2
7456112 Lee Nov 2008 B2
7471972 Rhodes et al. Dec 2008 B2
7473244 Frazier et al. Jan 2009 B2
7493232 Surina Feb 2009 B1
7534330 Yu et al. May 2009 B2
7583990 Goode, Jr. Sep 2009 B2
7599726 Goode, Jr. Oct 2009 B2
7613491 Boock Nov 2009 B2
7645263 Angel et al. Jan 2010 B2
7715893 Kamath et al. May 2010 B2
7725148 Shah et al. May 2010 B2
7768408 Reggiardo et al. Aug 2010 B2
7778680 Goode, Jr. Aug 2010 B2
7797028 Goode, Jr. Sep 2010 B2
7811231 Jin et al. Oct 2010 B2
7837654 Shumate et al. Nov 2010 B2
7885697 Brister et al. Feb 2011 B2
7905833 Brister et al. Mar 2011 B2
7917186 Kamath et al. Mar 2011 B2
7949382 Jina May 2011 B2
7959569 Goode et al. Jun 2011 B2
8005526 Martin et al. Aug 2011 B2
8010174 Goode, Jr. Aug 2011 B2
8022292 Arianpour et al. Sep 2011 B2
8064977 Boock et al. Nov 2011 B2
8088321 Ferguson et al. Jan 2012 B2
8094009 Allen et al. Jan 2012 B2
8108023 Mir et al. Jan 2012 B2
8110079 Gooding et al. Feb 2012 B2
8125331 Allen et al. Feb 2012 B2
8130095 Allen et al. Mar 2012 B2
8160665 Mischler et al. Apr 2012 B2
8160671 Kamath et al. Apr 2012 B2
8160834 Liang et al. Apr 2012 B2
8162901 Gonnelli et al. Apr 2012 B2
RE43399 Simpson et al. May 2012 E
8216138 McGarraugh Jul 2012 B1
8236368 Jung et al. Aug 2012 B2
8249684 Kamath et al. Aug 2012 B2
8257324 Prausnitz et al. Sep 2012 B2
8280475 Brister et al. Oct 2012 B2
8280476 Jina Oct 2012 B2
8284046 Allen et al. Oct 2012 B2
8287453 Li et al. Oct 2012 B2
8308960 Kalvesten et al. Nov 2012 B2
8346335 Harper et al. Jan 2013 B2
8376945 Hayter et al. Feb 2013 B2
8386004 Kamath et al. Feb 2013 B2
8423114 Simpson et al. Apr 2013 B2
8428678 Kamath et al. Apr 2013 B2
8452369 Huys et al. May 2013 B2
8463350 Kamath et al. Jun 2013 B2
8483793 Simpson et al. Jul 2013 B2
8506529 Yang Aug 2013 B1
8548553 Kamath et al. Oct 2013 B2
8565848 Brister et al. Oct 2013 B2
8574165 Marsh Nov 2013 B2
8617069 Bernstein et al. Dec 2013 B2
RE44695 Simpson et al. Jan 2014 E
8626257 Li et al. Jan 2014 B2
8637351 Kalvesten et al. Jan 2014 B2
8660628 Wang et al. Feb 2014 B2
8700114 Gottlieb et al. Apr 2014 B2
8708966 Allen et al. Apr 2014 B2
8798799 Deo et al. Aug 2014 B2
8815070 Wang et al. Aug 2014 B2
8870763 Yang et al. Oct 2014 B2
8882665 Yang et al. Nov 2014 B2
9008743 Hayter et al. Apr 2015 B2
9008745 Pushpala et al. Apr 2015 B2
9055901 Brister et al. Jun 2015 B2
9125625 Wang et al. Sep 2015 B2
9182368 Pushpala et al. Nov 2015 B2
9234872 Homyk et al. Jan 2016 B2
9248273 Guvanasen et al. Feb 2016 B2
9332934 Hayter et al. May 2016 B2
9336423 Goodnow et al. May 2016 B2
9357951 Simpson Jun 2016 B2
9386954 Saini et al. Jul 2016 B2
9387000 Corrie et al. Jul 2016 B2
9414778 Mao et al. Aug 2016 B2
9420965 Brauker et al. Aug 2016 B2
9532741 Brauker et al. Jan 2017 B2
9551698 Huys et al. Jan 2017 B2
9662056 Budiman et al. May 2017 B2
9737247 Wang et al. Aug 2017 B2
9743870 Wang et al. Aug 2017 B2
9743871 Simpson et al. Aug 2017 B2
9757061 Shults et al. Sep 2017 B2
9770211 Hayter et al. Sep 2017 B2
9804114 Rhodes et al. Oct 2017 B2
9933387 McCanna et al. Apr 2018 B1
9958409 Gerber et al. May 2018 B2
10022076 Hoss et al. Jul 2018 B2
10039480 Brauker et al. Aug 2018 B2
10046114 Biederman et al. Aug 2018 B1
10052055 Li et al. Aug 2018 B2
10092207 Windmiller Oct 2018 B1
10136846 Wang et al. Nov 2018 B2
10173042 Pushpala et al. Jan 2019 B2
10182748 Catt et al. Jan 2019 B2
10188333 Kamath et al. Jan 2019 B2
10228341 Katsuki et al. Mar 2019 B2
10299712 Brister et al. May 2019 B2
10327678 Gottlieb et al. Jun 2019 B2
10492708 Windmiller Dec 2019 B1
D875254 Cooke et al. Feb 2020 S
10549080 Pushpala et al. Feb 2020 B2
10610103 Brister et al. Apr 2020 B2
10709332 Brister et al. Jul 2020 B2
10743800 Larvenz et al. Aug 2020 B2
10780222 Ward et al. Sep 2020 B2
10820860 Pushpala et al. Nov 2020 B2
10881334 Facchinetti et al. Jan 2021 B2
10932700 Simpson et al. Mar 2021 B2
10983083 Harding et al. Apr 2021 B2
11020026 Boock et al. Jun 2021 B2
11035872 Boutelle et al. Jun 2021 B2
11045142 Windmiller et al. Jun 2021 B1
11051724 Pace et al. Jul 2021 B2
11123532 Pushpala et al. Sep 2021 B2
11179068 Pace et al. Nov 2021 B2
11197985 Pushpala et al. Dec 2021 B2
11272866 Pushpala et al. Mar 2022 B2
11272885 Pushpala et al. Mar 2022 B2
11291390 Pushpala et al. Apr 2022 B2
11331022 Halac et al. May 2022 B2
11359300 Beer et al. Jun 2022 B1
11406818 Windmiller Aug 2022 B2
11478194 Windmiller et al. Oct 2022 B2
11596332 Shults et al. Mar 2023 B2
11654270 Mansfield, III et al. May 2023 B2
D988160 Morelock Jun 2023 S
11672965 Mansfield, III et al. Jun 2023 B2
D996999 Morelock Aug 2023 S
D1012744 Morelock Jan 2024 S
11857344 Windmiller et al. Jan 2024 B2
11872055 Tangney et al. Jan 2024 B2
D1013544 Morelock Feb 2024 S
11904127 Mansfield, III et al. Feb 2024 B2
11963796 Windmiller et al. Apr 2024 B1
20020004640 Conn et al. Jan 2002 A1
20020020688 Sherman et al. Feb 2002 A1
20020055704 Scott et al. May 2002 A1
20020072784 Norman, Jr. et al. Jun 2002 A1
20020105080 Speakman Aug 2002 A1
20020187556 Shartle Dec 2002 A1
20030068666 Zweig Apr 2003 A1
20030088166 Say May 2003 A1
20030095582 Ackley May 2003 A1
20030100040 Bonnecaze et al. May 2003 A1
20030104119 Wilson et al. Jun 2003 A1
20030135158 Gonnelli Jul 2003 A1
20030208167 Prausnitz et al. Nov 2003 A1
20030225360 Eppstein et al. Dec 2003 A1
20030235817 Bartkowiak et al. Dec 2003 A1
20040065158 Schrepfer et al. Apr 2004 A1
20040082875 Donoghue et al. Apr 2004 A1
20040220625 Silvestri et al. Nov 2004 A1
20050036020 Li et al. Feb 2005 A1
20050101841 Kaylor et al. May 2005 A9
20050137536 Gonnelli Jun 2005 A1
20050209565 Yuzhakov et al. Sep 2005 A1
20050267440 Herman et al. Dec 2005 A1
20050272989 Shah et al. Dec 2005 A1
20060015061 Kuo et al. Jan 2006 A1
20060016700 Brister et al. Jan 2006 A1
20060173259 Flaherty et al. Aug 2006 A1
20060264716 Zander Nov 2006 A1
20060281121 Unger et al. Dec 2006 A1
20070078445 Malloy Apr 2007 A1
20070169533 Shah et al. Jul 2007 A1
20070170054 Wilsey Jul 2007 A2
20070213044 Steingart et al. Sep 2007 A1
20070282246 Henley Dec 2007 A1
20080009800 Nickel Jan 2008 A1
20080009801 Nickel Jan 2008 A1
20080027369 Carter et al. Jan 2008 A1
20080033269 Zhang Feb 2008 A1
20080097280 Martin et al. Apr 2008 A1
20080097352 Beck et al. Apr 2008 A1
20080119707 Stafford May 2008 A1
20080154107 Jina Jun 2008 A1
20080156661 Cooper et al. Jul 2008 A1
20080213461 Gill et al. Sep 2008 A1
20080221408 Hoarau et al. Sep 2008 A1
20080234562 Jina Sep 2008 A1
20080255434 Hayter et al. Oct 2008 A1
20080275327 Faarbaek et al. Nov 2008 A1
20090057148 Wieder et al. Mar 2009 A1
20090066348 Shin et al. Mar 2009 A1
20090069651 Zimmermann et al. Mar 2009 A1
20090069697 Frazier et al. Mar 2009 A1
20090084678 Joshi et al. Apr 2009 A1
20090088652 Tremblay Apr 2009 A1
20090090623 Chuang et al. Apr 2009 A1
20090099427 Jina et al. Apr 2009 A1
20090101498 Papadimitrakopoulos et al. Apr 2009 A1
20090118672 Gonnelli et al. May 2009 A1
20090131778 Jina et al. May 2009 A1
20090143761 Cantor et al. Jun 2009 A1
20090152598 Baek et al. Jun 2009 A1
20090191616 Lu et al. Jul 2009 A1
20090198118 Hayter et al. Aug 2009 A1
20090218239 Gooding et al. Sep 2009 A1
20090259118 Feldman et al. Oct 2009 A1
20090294306 Feldman et al. Dec 2009 A1
20100006451 Gordon et al. Jan 2010 A1
20100021637 Revol et al. Jan 2010 A1
20100022416 Flemming et al. Jan 2010 A1
20100025238 Gottlieb et al. Feb 2010 A1
20100030045 Gottlieb et al. Feb 2010 A1
20100049021 Jina et al. Feb 2010 A1
20100052892 Allen et al. Mar 2010 A1
20100052897 Allen et al. Mar 2010 A1
20100052898 Allen et al. Mar 2010 A1
20100052915 Allen et al. Mar 2010 A1
20100056873 Allen et al. Mar 2010 A1
20100137779 Seitz Jun 2010 A1
20100200538 Petisce et al. Aug 2010 A1
20100279377 Shah et al. Nov 2010 A1
20100286803 Tillotson Nov 2010 A1
20110027127 Simpson et al. Feb 2011 A1
20110077490 Simpson et al. Mar 2011 A1
20110105871 Zimmermann et al. May 2011 A1
20110140703 Chiao et al. Jun 2011 A1
20110210017 Lai et al. Sep 2011 A1
20110224515 Mir et al. Sep 2011 A1
20110230736 Tepper et al. Sep 2011 A1
20110237925 Yue et al. Sep 2011 A1
20110247934 Wang et al. Oct 2011 A1
20110275918 Yamashita et al. Nov 2011 A1
20110306853 Black et al. Dec 2011 A1
20110319787 Lamoise et al. Dec 2011 A1
20120018302 Shiraki et al. Jan 2012 A1
20120037515 Solanki Feb 2012 A1
20120067734 Wang et al. Mar 2012 A1
20120078071 Bohm et al. Mar 2012 A1
20120123232 Najarian et al. May 2012 A1
20120172692 Tamada et al. Jul 2012 A1
20120209244 Gray Aug 2012 A1
20120277629 Bernstein et al. Nov 2012 A1
20120323097 Chowdhury Dec 2012 A9
20130053660 Shieh Feb 2013 A1
20130065257 Wang et al. Mar 2013 A1
20130135158 Faraone et al. May 2013 A1
20130144131 Wang et al. Jun 2013 A1
20130158376 Hayter et al. Jun 2013 A1
20130225956 Huang et al. Aug 2013 A1
20130281808 Shieh Oct 2013 A1
20130338746 Guvanasen et al. Dec 2013 A1
20130345597 Hagino et al. Dec 2013 A1
20140135679 Mann et al. May 2014 A1
20140259652 Pushpala et al. Sep 2014 A1
20140275897 Pushpala et al. Sep 2014 A1
20140275899 Gottlieb et al. Sep 2014 A1
20140275907 Feldman et al. Sep 2014 A1
20140303471 Rajaraman et al. Oct 2014 A1
20140336487 Wang et al. Nov 2014 A1
20140378804 Kalvesten Dec 2014 A1
20150073238 Matsumoto et al. Mar 2015 A1
20150126834 Wang et al. May 2015 A1
20150208970 Huang Jul 2015 A1
20150243851 Lee et al. Aug 2015 A1
20150276758 Addisu Oct 2015 A1
20150313527 Renlund Nov 2015 A1
20160029937 Sia et al. Feb 2016 A1
20160058342 Maiz-Aquinaga et al. Mar 2016 A1
20160095541 Wang et al. Apr 2016 A1
20160095547 Wang et al. Apr 2016 A1
20160139069 Wang May 2016 A1
20160157764 Di Palma et al. Jun 2016 A1
20160158514 Stoeber Jun 2016 A1
20160166184 Teng et al. Jun 2016 A1
20160258945 Malima et al. Sep 2016 A1
20160270704 DeTurk Sep 2016 A1
20160296149 Polsky et al. Oct 2016 A1
20160302687 Lee et al. Oct 2016 A1
20160370377 Ahmad Dec 2016 A1
20170003766 Budiman Jan 2017 A1
20170007813 Negi et al. Jan 2017 A1
20170035331 Parajape et al. Feb 2017 A1
20170055835 Scherer et al. Mar 2017 A1
20170086713 Pushpala et al. Mar 2017 A1
20170108459 Katsuki et al. Apr 2017 A1
20170127989 Feldman et al. May 2017 A1
20170128009 Pushpala et al. May 2017 A1
20170164881 Fujita et al. Jun 2017 A1
20170251959 Feldman et al. Sep 2017 A1
20170251960 Crouther et al. Sep 2017 A1
20170347925 Wang et al. Dec 2017 A1
20180116572 Simpson et al. May 2018 A1
20180140235 Pushpala et al. May 2018 A1
20180279929 Huang et al. Oct 2018 A1
20180317820 Pace et al. Nov 2018 A1
20180338712 Cass et al. Nov 2018 A1
20180340203 Holmes et al. Nov 2018 A1
20190008425 Srinivasan et al. Jan 2019 A1
20190022365 Chowdhury et al. Jan 2019 A1
20190029577 Koelker et al. Jan 2019 A1
20190090811 Reitz et al. Mar 2019 A1
20190091455 Reitz et al. Mar 2019 A1
20190094169 Shah et al. Mar 2019 A1
20190101551 Plaxco et al. Apr 2019 A1
20190110724 Kamath et al. Apr 2019 A1
20190125223 Wang et al. May 2019 A1
20190167167 Mitchell et al. Jun 2019 A1
20190170739 Garner et al. Jun 2019 A1
20190201675 Miller et al. Jul 2019 A1
20190209095 Kamath et al. Jul 2019 A1
20190223795 Patolsky et al. Jul 2019 A1
20190224712 Petisce et al. Jul 2019 A1
20190231263 Ribet et al. Aug 2019 A1
20190241926 Mckinlay et al. Aug 2019 A1
20190261907 Brister et al. Aug 2019 A1
20190274599 Polsky et al. Sep 2019 A1
20190274600 Pesantez et al. Sep 2019 A1
20190298210 Bennet et al. Oct 2019 A1
20190307379 Boock et al. Oct 2019 A1
20190309433 Sattayasamitsathit et al. Oct 2019 A1
20190310219 Boock Oct 2019 A1
20190357827 Li et al. Nov 2019 A1
20200000387 Gerhardt et al. Jan 2020 A1
20200029876 Brister et al. Jan 2020 A1
20200037938 Rong et al. Feb 2020 A1
20200085341 Windmiller Mar 2020 A1
20200101286 Windmiller et al. Apr 2020 A1
20200121902 Pushpala et al. Apr 2020 A1
20200178853 Pushpala et al. Jun 2020 A1
20200187778 Brister et al. Jun 2020 A1
20200214566 Allen et al. Jul 2020 A1
20200254240 Windmiller et al. Aug 2020 A1
20200297997 Windmiller et al. Sep 2020 A1
20200305771 Feldman et al. Oct 2020 A1
20200330007 Garai et al. Oct 2020 A1
20200359949 Brauker et al. Nov 2020 A1
20200390395 Pushpala et al. Dec 2020 A1
20200405234 Pushpala et al. Dec 2020 A1
20210045663 Simpson et al. Feb 2021 A1
20210045665 Simpson et al. Feb 2021 A1
20210045666 Simpson et al. Feb 2021 A1
20210100452 Brister et al. Apr 2021 A1
20210100504 Pushpala et al. Apr 2021 A1
20210100505 Pushpala et al. Apr 2021 A1
20210183508 Parker et al. Jun 2021 A1
20210187286 Windmiller et al. Jun 2021 A1
20210190719 LaTour et al. Jun 2021 A1
20210236057 Pushpala et al. Aug 2021 A1
20210321942 Pushpala et al. Oct 2021 A1
20210345916 Boock et al. Nov 2021 A1
20210353229 Pierart et al. Nov 2021 A1
20210379370 Windmiller et al. Dec 2021 A1
20210386338 Zhang et al. Dec 2021 A1
20210393201 Morelock et al. Dec 2021 A1
20220031209 Windmiller et al. Feb 2022 A1
20220031244 Windmiller et al. Feb 2022 A1
20220047190 Taylor et al. Feb 2022 A1
20220054813 Pushpala et al. Feb 2022 A1
20220054814 Pushpala et al. Feb 2022 A1
20220104773 Lee et al. Apr 2022 A1
20220151516 Wang et al. May 2022 A1
20220151518 Pushpala et al. May 2022 A1
20220151519 Pushpala et al. May 2022 A1
20220151558 Pushpala et al. May 2022 A1
20220175278 Windmiller et al. Jun 2022 A1
20220175279 Pushpala et al. Jun 2022 A1
20220175282 Hoss et al. Jun 2022 A1
20220214300 Wang et al. Jul 2022 A1
20220225901 Chapman et al. Jul 2022 A1
20220233107 Pushpala et al. Jul 2022 A1
20220249189 Choi et al. Aug 2022 A1
20220257181 Wang et al. Aug 2022 A1
20220298291 Shin et al. Sep 2022 A1
20220322975 Baker et al. Oct 2022 A1
20220322977 Simpson et al. Oct 2022 A1
20220370011 Windmiller et al. Nov 2022 A1
20230003725 Wang et al. Jan 2023 A1
20230074798 Tangney Mar 2023 A1
20230094419 Mansfield, III et al. Mar 2023 A1
20230099617 Mansfield, III et al. Mar 2023 A1
20230137258 Windmiller May 2023 A1
20230190147 Campbell et al. Jun 2023 A1
20230256220 Mansfield et al. Aug 2023 A1
20230301552 Mallires et al. Sep 2023 A1
20230310823 Mansfield, III et al. Oct 2023 A1
20230414102 Allen et al. Dec 2023 A1
20240008777 Fuchs et al. Jan 2024 A1
20240081740 Windmiller et al. Mar 2024 A1
20240164719 Campbell et al. May 2024 A1
Foreign Referenced Citations (84)
Number Date Country
101068591 Nov 2007 CN
112617822 Apr 2021 CN
113717955 Nov 2021 CN
102015209669 Dec 2016 DE
1006868 Jun 2004 EP
1 372 602 Apr 2007 EP
1792565 Oct 2008 EP
1 187 653 Mar 2010 EP
2 898 821 Dec 2017 EP
3364183 Aug 2018 EP
3 381 370 Oct 2018 EP
H0222552 Jan 1990 JP
H-02-031741 Feb 1990 JP
H-07-275227 Oct 1995 JP
2003-038464 Feb 2003 JP
2003-038465 Feb 2003 JP
2004180773 Jul 2004 JP
2005-087613 Apr 2005 JP
2006-510467 Apr 2005 JP
2005-525141 Aug 2005 JP
2005-322591 Nov 2005 JP
2008-512162 Apr 2008 JP
2008-540013 Nov 2008 JP
2017108763 Jun 2017 JP
2019205852 Dec 2019 JP
2020170011 Oct 2020 JP
2022501100 Jan 2022 JP
10-2016-0108111 Sep 2016 KR
WO-0074763 Dec 2000 WO
WO-0074763 Dec 2000 WO
WO-2006060106 Jun 2006 WO
WO2006093422 Sep 2006 WO
WO-2006116242 Nov 2006 WO
WO-2006116242 Nov 2006 WO
WO-2007040938 Apr 2007 WO
WO2009034313 Mar 2009 WO
WO2009064164 May 2009 WO
WO-2009124095 Oct 2009 WO
WO-2010014959 Feb 2010 WO
WO-2010014959 Feb 2010 WO
WO-2010022252 Feb 2010 WO
WO-2010022252 Feb 2010 WO
WO-2010045247 Apr 2010 WO
WO-2010059276 May 2010 WO
WO2010120364 Oct 2010 WO
WO-2011056095 May 2011 WO
WO2012020332 Feb 2012 WO
WO-2012142625 Oct 2012 WO
WO-2012142625 Oct 2012 WO
WO2013058879 Apr 2013 WO
WO-2014120114 Aug 2014 WO
WO2015073459 May 2015 WO
WO-2016189301 Dec 2016 WO
WO-2017129980 Aug 2017 WO
WO-2017189707 Nov 2017 WO
WO-2018017196 Jan 2018 WO
WO-2018071265 Apr 2018 WO
WO-2018170363 Sep 2018 WO
WO2018164886 Sep 2018 WO
WO-2019046333 Mar 2019 WO
WO-2019156934 Aug 2019 WO
WO-2019222615 Nov 2019 WO
WO-2019239258 Dec 2019 WO
WO-2020023804 Jan 2020 WO
WO-2020117918 Jun 2020 WO
WO-2021015389 Jan 2021 WO
WO-2021025260 Feb 2021 WO
WO-2021062475 Apr 2021 WO
WO-2021086690 May 2021 WO
WO-2021118124 Jun 2021 WO
WO-2021118431 Jun 2021 WO
WO-2021216186 Oct 2021 WO
WO-2021216186 Dec 2021 WO
WO-2022026764 Feb 2022 WO
WO-2022066985 Mar 2022 WO
WO-2022066992 Mar 2022 WO
WO-2022090741 May 2022 WO
WO-2022136785 Jun 2022 WO
WO-2022240700 Nov 2022 WO
WO-2023055755 Apr 2023 WO
WO-2023064877 Apr 2023 WO
WO-2023133468 Jul 2023 WO
WO-2023229662 Nov 2023 WO
WO-2024010827 Jan 2024 WO
Non-Patent Literature Citations (145)
Entry
Bantle, J.P. et al. (1997). “Glucose measurement in patients with diabetes mellitus with dermal interstitial fluid,” J. Lab. Clin. Med. 130:436-441.
Beckles, G.L. et al. (2016). “Disparities in the prevalence of diagnosed diabetes—United States, 1999-2002 and 2011-2014,” MMWR 65:1265-1269.
Castle, J.R. et al. (2012). “The accuracy benefit of multiple amperometric glucose sensors in people (with type 1 diabetes,” Diabetes Care 35:706-710.
Chang, H. et al. (2017). “A swellable microneedle patch to rapidly extract skin interstitial fluid for timely metabolic analysis,” Adv. Mater. 29:1702243.
Dexcom (2020). Analyst Day Presentation, 27 total pages.
Dexcom (2020). Analyst Day Presentation, 19 total pages.
Diabetes Care (2021). “7. Diabetes Technology: Standards of Medical Care in Diabetes—2021,” Diabetes Care 44(Supplement 1):S85-S99.
Donnelly, R.F. et al. (2007). “Microstructured Devices for Transdermal Drug Delivery and Minimally-Invasive Patient Monitoring,” Recent Patents on Drug Delivery & Formulation 1:195-200.
Extended European Search Report mailed on May 8, 2015, for EP Application No. 12 842 020.5, filed on Aug. 31, 2012, 7 pages.
Fang, M. et al. (2021). “Trends in Diabetes Treatment and Control in U.S. Adults, 1999-2018,” N. Engl. Med. 384:2219-2228.
Final Office Action mailed on Aug. 19, 2016, for U.S. Appl. No. 14/965,755, filed Dec. 10, 2015, 17 pages.
Final Office Action mailed on Nov. 28, 2016, for U.S. Appl. No. 14/342,536, filed Jul. 30, 2014, 34 pages.
Final Office Action mailed on May 18, 2018, for U.S. Appl. No. 15/687,145, filed Aug. 25, 2017, 23 pages.
Final Office Action mailed on Dec. 7, 2020, for U.S. Appl. No. 15/961,793, filed Apr. 24, 2018, 13 pages.
Final Office Action mailed on May 21, 2021, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 11 pages.
Final Office Action mailed on Jun. 9, 2021, for U.S. Appl. No. 16/169,939, filed Oct. 24, 2018, 24 pages.
French, D.P. et al. (2008). “Original Article: Psychological Care Self-monitoring of blood glucose changed non-insulin-treated Type 2 diabetes patients' beliefs about diabetes and self-monitoring in a randomized trial,” Diav. Med. 25:1218-1228.
Gittard, S.D. et al. (2009). “Fabrication of Polymer Microneedles Using a Two-Photon Polymerization Jand Micromolding Process,” J. Diabetes Sci. Technol. 3:304-311.
Grady, M. et al. (2017). “Examining the Impact of a Novel Blood Glucose Monitor With Color Range Indicator on Decision-Making in Patients With Type 1 and Type 2 Diabetes and its Association With Patient Numeracy Level,” JMIR Diabetes 2:e24.
Grady, M. et al. (2018). “Use of Blood Glucose Meters Featuring Color Range Indicators Improves Glycemic Control in Patients With Diabetes in Comparison to Blood Glucose Meters Without Color (ACCENTS Study),” J. Diab. Sci. Tech. 12:1211-1219.
Groenendaal, W. et al. (2008). “Modeling Glucose and Water Dynamics in Human Skin,” Diab. Tech. Therap. 10:283-293.
International Search Report malled on Feb. 4, 2021, for PCT Application No. PCT/US2020/056517, filed on Oct. 20, 2020, 2 pages.
International Search Report mailed on Sep. 10, 2020, for PCT Application No. PCT/US2020/037379, filed on Jun. 12, 2020, 2 pages.
International Search Report mailed on Dec. 30, 2021, for PCT Application No. PCT/US2021/043786, filed on Jul. 29, 2021, 7 pages.
International Search Report mailed on Jun. 27, 2013, for PCT Application No. PCT/US2012/053544, filed on Aug. 31, 2012, 4 pages.
Jeon, G. et al. (2011). “Electrically Actuatable Smart Nanoporous Membrane for Pulsatile Drug Release,” Nano Lett. 11:1284-1288.
Jina, A et al. (2014). “Design, development, and evaluation of a novel microneedle array-based continuous glucose monitor,” J. Diabetes Sci. Technol. 8:483-487.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2008). “Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes,” N. Engl. Med. 359:1464-1476.
Karter, A.J. et al. (2021). “Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes,” JAMA 325:2273-2284.
Lhernould, M.S. et al. (2015). “Review of Patents for Microneedle Application Devices Allowing Fluid Injections Through the Skin,” Recent Patents on Drug Delivery & Formulation 9:146-157.
Malitesta et al. (1990), “Glucose fast-response amperometric sensor based on glucose oxidase immobilized in an electropolymerized poly(o-phenylenediamine) film,” Anal. Chem. 62:2735-2740.
Martens, T. et al. (2021). “Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin A Randomized Clinical Trial,” JAMA 325:2262-2272.
McClatchey, P.M. et al. (2019). “Fibrotic Encapsulation Is the Dominant Source of Continuous Glucose Monitor Delays,” Diabetes 68:1892-1901.
Miller, P.R. et al. (2011). “Integrated carbon fiber electrodes within hollow polymer microneedles for transdermal electrochemical sensing,” BioMicrofluidics 5(1):013415.
Neerken, S. et al. (2004). “Characterization of age-related effects in human skin: A comparative study that applies confocal laser scanning microscopy and optical coherence tomography,” J. Biomed. Optics 9:274-281.
Non-Final Office Action mailed on Mar. 10, 2016, for U.S. Appl. No. 14/965,755, filed Dec. 10, 2015, 15 pages.
Non-Final Office Action mailed on Mar. 30, 2016, for U.S. Appl. No. 14/342,536, filed Jul. 30, 2014, 31 pages.
Non-Final Office Action mailed on Mar. 9, 2017, for U.S. Appl. No. 14/965,755, filed Dec. 10, 2015, 17 pages.
Non-Final Office Action mailed on Apr. 6, 2017, for U.S. Appl. No. 14/342,536, filed Jul. 30, 2014, 32 pages.
Non-Final Office Action mailed on Nov. 1, 2017, for U.S. Appl. No. 15/687,145, filed Aug. 25, 2017, 19 pages.
Non-Final Office Action mailed on Jan. 19, 2018, for U.S. Appl. No. 14/843,926, filed Sep. 2, 2015, 11 pages.
Non-Final Office Action mailed on Apr. 13, 2020, for U.S. Appl. No. 15/961,793, filed Apr. 24, 2018, 13 pages.
Non-Final Office Action mailed on Sep. 3, 2020, for U.S. Appl. No. 16/169,939, filed Oct. 24, 2018, 19 pages.
Non-Final Office Action mailed on Oct. 16, 2020, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 13 pages.
Non-Final Office Action mailed on Nov. 4, 2021, for U.S. Appl. No. 16/169,939, filed Oct. 24, 2018, 20 pages.
Non-Final Office Action mailed on Nov. 26, 2021, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 15 pages.
Non-Final Office Action mailed on Nov. 29, 2021, for U.S. Appl. No. 17/389,153, filed Jul. 29, 2021, 14 pages.
Notice of Allowance mailed on Jul. 6, 2017, for U.S. Appl. No. 14/965,755, filed Dec. 10, 2015, 12 pages.
Notice of Allowance mailed on Jul. 12, 2017, for U.S. Appl. No. 14/342,536, filed Jul. 30, 2014, 14 pages.
Notice of Allowance mailed on Feb. 13, 2018, for U.S. Appl. No. 14/843,926, filed Sep. 2, 2015, 8 pages.
Notice of Allowance mailed on Aug. 24, 2018, for U.S. Appl. No. 15/687,145, filed Aug. 25, 2017, 7 pages.
Notice of Allowance mailed on May 25, 2021, for U.S. Appl. No. 15/961,793, filed Apr. 24, 2018, 11 pages.
Rigla, M. et al. (2018). “Human Subcutaneous Tissue Response to Glucose Sensors: Macrophages Accumulation Impact on Sensor Accuracy,” Diabetes Technology & Therapeutics 20:296-302.
Sachdeva, V. et al. (2011). “Microneedles and their applications,” Recent Patents on Drug Delivery & Formulation 5:95-132.
Sheikh, Z. et al. (2015). “Macrophages, Foreign Body Giant Cells and Their Response to Implantable Biomaterials,” Materials 8:5671-5701.
Shi, T. et al. (2016). “Modeling and Measurement of Correlation between Blood and Interstitial Glucose Changes,” J. Diab. Res. vol. 2016, 9 pages.
Singh, T.R.R. et al. (2010). “Microporation techniques for enhanced delivery of therapeutic agents,” Recent Patents on Drug Delivery & Formulation 4:1-17.
Texas Instruments (Sep. 2007). Data sheet for a LMP2234 quad micropower, 1.6V, precision, operational amplifier with CMOS input, Sep. 2007, revised Mar. 2013.
Windmiller, J.R. (2012). “Molecular scale biocomputing: An enzyme logic approach,” University of California, San Diego, A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Electrical Engineering (Photonics), 78 total pages.
Windmiller, J.R. et al. (2011). “Bicomponent microneedle array biosensor for minimally-invasive glutamate monitoring,” Electroanalysis 23:2302-2309.
Windmiller, J.R. et al. (2011). “Microneedle array-based carbon paste amperometric sensors and blosensors,” Analyst 136:1846-1851.
Written Opinion of the International Searching Authority mailed on Feb. 4, 2021, for PCT Application No. PCT/US2020/056517, filed on Oct. 20, 2020, 5 pages.
Written Opinion of the International Searching Authority mailed on Sep. 10, 2020, for PCT Application No. PCT/US2020/037379, filed on Jun. 12, 2020, 4 pages.
Written Opinion of the International Searching Authority mailed on Dec. 30, 2021, for PCT Application No. PCT/US2021/043786, filed on Jul. 29, 2021, 10 pages.
Written Opinion of the International Searching Authority mailed on Jun. 27, 2013, for PCT Application No. PCT/US2012/053544, filed on Aug. 31, 2012, 15 pages.
Yoon, Y. et al. (2013). “Fabrication of a Microneedle/CNT Hierarchical Micro/Nano Surface Electrochemical Sensor and Its In-Vitro Glucose Sensing Characterization,” Sensors 13:16672-16681.
Abbot press release (2020). “New late-breaking data show use of abbott's Freestyle® Libre System significantly reduces HBA1C levels in people with type 2 diabetes using insulin or not,” 3 pages.
American Diabetes Association® Press Release (2020). “American Diabetes Association® Applauds policymakers' Focus on Addressing High Costs of Insulin for Seven Million Americans,” 4 pages.
Cao, J. et al. (2017). “Validation of capillary blood analysis and capillary testing mode on the epoc Point of Care system,” Pract. Lab. Med. 9:24-27.
Final Office Action mailed on May 9, 2022, for U.S. Appl. No. 17/389,153, filed Jul. 29, 2021, 17 pages.
Final Office Action mailed on Aug. 15, 2022, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 15 pages.
International Search Report mailed on Aug. 29, 2022, for PCT Application No. PCT/US2022/028196, filed on May 6, 2022, 2 pages.
Non-Final Office Action mailed on Apr. 8, 2022, for U.S. Appl. No. 17/650,056, filed Feb. 4, 2022, 14 pages.
Notice of Allowance mailed on Sep. 12, 2022, for U.S. Appl. No. 17/389,153, filed Jul. 29, 2021, 8 pages.
Polonsky, W.H. et al. (2011). “A survey of blood glucose monitoring in patients with type 2 diabetes: Are recommendations from health care professionals being followed?” Curr. Med. Res. & Opinion 27:31-37.
Written Opinion of the International Searching Authority mailed on Aug. 29, 2022, for PCT Application No. PCT/US2022/028196, filed on May 6, 2022, 5 pages.
Extended European Search Report mailed on Oct. 27, 2022, for EP Application No. 21 850 331.6, filed on Jul. 29, 2021, 8 pages.
International Search Report mailed on Sep. 30, 2021, for PCT Application No. PCT/US2021/040385, filed on Jul. 2, 2021, 2 pages.
Mohan, A.M. (2017). “Continuous minimally-invasive alcohol monitoring using microneedle sensor arrays,” Biosensors and Bioelectronics 91:574-579.
Non-Final Office Action mailed on Dec. 21, 2022, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 12 pages.
Non-Final Office Action mailed on Jan. 27, 2023, for U.S. Appl. No. 17/971,415, filed Oct. 21, 2022, 15 pages.
Non-Final Office Action mailed on Feb. 16, 2023, for U.S. Appl. No. 17/738,990, 8 pages.
Non-Final Office Action mailed on Mar. 9, 2023, for U.S. Appl. No. 17/389,156, filed Jul. 29, 2021, 24 pages.
Swedish Search Report mailed on Feb. 3, 2023 for SE Application No. 2350067-1, 7 pages.
Written Opinion of the International Searching Authority mailed on Sep. 30, 2021, for PCT Application No. PCT/US2021/040385, filed on Jul. 2, 2021, 2 pages.
Al Hayek et al., “Patient Satisfaction and Clinical Efficacy of Novel Blood Glucose Meters Featuring Color Range Indicators in Patients With Type 2 Diabetes: A Prospective Study” Cureus Oct. 27, 2020; 12(10):e11195. 8 pages.
Allen et al., “Continuous glucose monitoring counseling improves physical activity behaviors of individuals with type 2 diabetes: A randomized clinical trial” Diabetes Res Clin Pract. Jun. 2008; 80(3): 371-379. doi:10.1016/j.diabres.2008.01.006.
Barrett et al., “Risk for Newly Diagnosed Diabetes 30 Days After SARS-CoV-2 Infection Among Persons Aged 18 Years—United States, Mar. 1, 2020-Jun. 28, 2021” MMWR Morb Mortal Wkly Rep. Jan. 14, 2022; 71(2):59-65. doi: 10.15585/mmwr.mm7102e2.
Brown, “Design of Electronics for Wearable Electrochemical Sensors” University of California, San Diego, Master's Thesis (2019) 48 pages.
Centers for Disease Control, “National Diabetes Statistics Report 2020 Estimates of Diabetes and Its Burden in the United States” (2020) 32 pages.
Dunkin et al., “Scarring occurs at a critical depth of skin injury: precise measurement in a graduated dermal scratch in human volunteers” Plast Reconstr Surg. May 2007; 119(6): 1722-1732. doi: 10.1097/01.prs.0000258829.07399.f0.
Ehrhardt et al., “Behavior Modification in Prediabetes and Diabetes: Potential Use of Real-Time Continuous Glucose Monitoring ” Journal of Diabetes Science and Technology Mar. 2019; 13(2):271-275.
Ehrhardt et al., “Continuous Glucose Monitoring As a Behavior Modification Tool” Clin Diabetes. Apr. 2020; 38(2):126-131. doi: 10.2337/cd19-0037.
Ehrhardt et al., “The Effect of Real-Time Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Mellitus” Journal of Diabetes Science and Technology May 2011; 5(3):668-675.
Extended European Search Report mailed on Mar. 30, 2023, for European Application No. EP20881425.1, 8 pages.
Final Office Action mailed on Aug. 29, 2023, for U.S. Appl. No. 18/086,543, filed Dec. 21, 2022, 17 pages.
Fonda et al., “The Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes” Journal of Diabetes Science and Technology (2016) 10(4):898-904.
Han et al., “The End of the Road for the YSI 2300 Analyzer: Where Do We Go Now?” Journal of Diabetes Science and Technology (2020) 14(3):595-600.
Han et al., “The YSI 2300 Analyzer Replacement Meeting Report” Journal of Diabetes Science and Technology (2020) 14(3):679-686.
Non-Final Office Action mailed on May 24, 2023, for U.S. Appl. No. 18/086,543, filed Dec. 21, 2022, 19 pages.
Non-Final Office Action mailed on Jun. 2, 2023, for U.S. Appl. No. 17/367,274, filed Jul. 2, 2021, 27 pages.
Non-Final Office Action mailed on Jun. 20, 2023, for U.S. Appl. No. 17/073,331, filed Oct. 17, 2020, 10 pages.
Non-Final Office Action mailed on Sep. 15, 2023, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 12 pages.
Notice of Allowance mailed on Jun. 12, 2023, for U.S. Appl. No. 17/971,415, filed Oct. 21, 2022, 14 pages.
Notice of Allowance mailed on Jun. 12, 2023, for U.S. Appl. No. 17/738,990, filed May 6, 2022, 7 pages.
Notice of Allowance mailed on Sep. 25, 2023, for U.S. Appl. No. 17/971,415, filed Oct. 21, 2022, 8 pages.
Notice of Allowance mailed on Sep. 26, 2023, for U.S. Appl. No. 17/738,990, filed May 6, 2022, 7 pages.
Sharifi et al., “Redundancy in Glucose Sensing: Enhanced Accuracy and Reliability of an Electrochemical Redundant Sensor for Continuous Glucose Monitoring” Journal of Diabetes Science and Technology (2016) 10(3):669-678.
Turner et al., “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)” The Lancet Sep. 1998; 352(9131):837-853.
Vigersky et al., “Short- and Long-Term Effects of Real-Time Continuous Glucose Monitoring in Patients with Type 2 Diabetes” Diabetes Care Jan. 2012; 35:32-38.
Wolicki et al., “Epidemiology and Prevention of Vaccine-Preventable Diseases: Chapter 6: Vaccine Administration” Centers for Disease Control and Prevention (2021) 17 pages.
World Health Organization, “Diabetes”, Sep. 16, 2022, 5 pages.
Young et al., “Glucose Self-monitoring in Non-Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings: A Randomized Trial” JAMA Intern Med. Jul. 2017; 177(7):920-929.
American Diabetes Association, “Diabetes and Emotional Health: A Practical Guide for Health Professionals Supporting Adults with Type 1 and Type 2 Diabetes” U.S. Edition (2021), 214 pages.
American Diabetes Association Professional Practice Committee, “6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2024” Diabetes Care Jan. 1, 2024; 47(Suppl 1):S111-S125.
American Diabetes Association Professional Practice Committee, “7. Diabetes Technology: Standards of Medical Care in Diabetes—2022” Diabetes Care Jan. 1, 2022; 45(Suppl 1):S97-S112.
Chen et al., “Electrochemically Mediated Electrodeposition/Electropolymerization To Yield a Glucose Microbiosensor with Improved Characteristics” Anal. Chem. (2002) 74:368-372.
Diabetes Control and Complications Trial Research Group, “The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus” N Engl J Med Sep. 30, 1993; 329(14):977-986.
Elsayed et al., “2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2023” Diabetes Care Jan. 1, 2023; 46(Suppl 1):S19-S40.
Extended European Search Report for European Application No. EP20898007.8 dated Nov. 29, 2023, 9 pages.
Final Office Action mailed on Feb. 1, 2024, for U.S. Appl. No. 17/073,331, filed Oct. 17, 2020, 12 pages.
Final Office Action mailed on Feb. 8, 2024, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 15 pages.
Final Office Action mailed on Mar. 15, 2024, for U.S. Appl. No. 17/367,274, filed Jul. 2, 2021, 33 pages.
Final Office Action mailed on Nov. 27, 2023, for U.S. Appl. No. 17/389,156, filed Jul. 29, 2021, 29 pages.
International Search Report and Written Opinion for PCT Application No. PCT/US2020/064700, mail date Mar. 9, 2021, 11 pages.
International Search Report and Written Opinion mailed on Feb. 6, 2024, for International Application No. PCT/US2022/078819, filed on Oct. 27, 2022, 13 pages.
Mendes-Soares et al., “Assessment of a Personalized Approach to Predicting Postprandial Glycemic Responses to Food Among Individuals Without Diabetes” JAMA Network Open Feb. 1, 2019; 2(2):e188102. 13 pages.
Miller et al., “Hypoglycemia in patients with type 2 diabetes mellitus” Arch Intern Med Jul. 9, 2001; 161(13):1653-1659.
Newton et al., “Diabetic ketoacidosis in type 1 and type 2 diabetes mellitus: clinical and biochemical differences” Arch Intern Med Sep. 27, 2004; 164(17):1925-1931.
Non-Final Office Action mailed on Apr. 16, 2024, for U.S. Appl. No. 17/389,156, filed Jul. 29, 2021, 28 pages.
Non-Final Office Action mailed on Dec. 13, 2023, for U.S. Appl. No. 18/086,543, filed Dec. 21, 2022, 16 pages.
Notice of Allowance (Corrected) mailed on Apr. 19, 2024, for U.S. Appl. No. 18/086,543, filed Dec. 21, 2022, 4 pages.
Notice of Allowance (Corrected) mailed on Jan. 25, 2024, for U.S. Appl. No. 17/349,234, filed Jun. 16, 2021, 4 pages.
Notice of Allowance (Corrected) mailed on Mar. 18, 2024, for U.S. Appl. No. 17/349,234, filed Jun. 16, 2021, 9 pages.
Notice of Allowance mailed on Apr. 10, 2024, for U.S. Appl. No. 18/086,543, filed Dec. 21, 2022, 10 pages.
Notice of Allowance mailed on Dec. 20, 2023, for U.S. Appl. No. 17/349,234, filed Jun. 16, 2021, 13 pages.
Notice of Allowance mailed on Mar. 21, 2024, for U.S. Appl. No. 18/086,543, filed Dec. 21, 2022, 6 pages.
Notice of Allowance mailed on Mar. 4, 2024, for U.S. Appl. No. 18/086,543, filed Dec. 21, 2022, 10 pages.
Office Action and Swedish Search Report mailed on Oct. 17, 2023, for SE Application No. 2251496-2, 8 pages.
Segel et al., “Hypoglycemia-associated autonomic failure in advanced type 2 diabetes” Diabetes Mar. 2002; 51(3):724-733.
Shivers et al., “Turn it off!: diabetes device alarm fatigue considerations for the present and the future” J Diabetes Sci Technol May 1, 2013; 7(3):789-794.
Supplementary European Search Report mailed on Oct. 9, 2023, for EP Application No. 22808101.4, 4 pages.
Tanenbaum et al., “Diabetes Device Use in Adults With Type 1 Diabetes: Barriers to Uptake and Potential Intervention Targets” Diabetes Care Feb. 2017; 40(2):181-187.
UK Prospective Diabetes Study (UKPDS) Group, “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)” Lancet Sep. 12, 1998; 352(9131):837-853.
Non-Final Office Action mailed on May 24, 2024, for U.S. Appl. No. 18/527,128, filed Dec. 1, 2023, 17 pages.
Provisional Applications (1)
Number Date Country
62470204 Mar 2017 US